MYX 2.67% $4.62 mayne pharma group limited

Shorts Are Closing, page-10

  1. 1,395 Posts.
    lightbulb Created with Sketch. 266
    Has it occurred to you that KP may be stating
    his observational and researched facts. I like
    yourself was once seduced by glossary of facts.
    Believing in past Board and Senior Management
    ability to execute potential of products. Failure
    after failure whilst the grubs SR and co. accumulated
    huge shareholding and being handsomely rewarded
    by company. The Board under Corbett and his cohorts
    also increased their fees 150% plus whilst at the same
    time being completely out of their league in managing
    a great Pharmaceutical Company for a decade into
    the ground costing shareholders $billions. I assume
    KP like myself has been badly shaken financially by those incompetent Aar$#€>¥les. Then after sale of
    Metrics new management decided a Capital Return
    followed along with a special dividend is best for
    shareholders . I for one immediately made my opinion
    heard on this forum how stupid ? The only ones to
    gain on dividend were late entrant holders. OK they
    dropped Cap. Return. Had they not paid SD we now
    would not have had to go into debt again another
    10% of company virtually given away. I and I believe
    KP at the time although terribly disappointed in sale
    of Metric said buyback would be best for shareholders
    interest instead of SD and CR. What I am alluding to
    to is current management appears to have now settled
    min and may well be working in shareholder interests.
    But beware this company is on a knife edge and senior
    management know far more than us as to its future
    good or bad . They will look after themselves first.
    Take that as a fact. Retail shareholders have a controlling interest in Mayne and unless they are on the
    same page can easily be divided.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.